What is the status of Empliciti® (elotuzumab), the new immunotherapy?
In this week’s video, Dr. Brian G.M. Durie explains the recent FDA approval for the use of elotuzumab, pomalidomide, and dexamethasone (EPd) for the treatment of relapsed or refractory myeloma in patients who have received at least two prior therapies.
An important new combination – EPd – is now approved and available
If you have a question that you’d like to suggest for a future episode of Ask Dr. Durie, please submit it to [email protected].
To reach the IMF InfoLine Coordinators, please call 800.452.2873 or email them at [email protected].
Dr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.